NEW YORK, Aug 23 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Friday it is negotiating with plaintiffs' lawyers who have opposed the company's proposed settlement of lawsuits alleging its baby powder and other talc products caused cancer, seeking to eliminate holdouts to the deal.
Tylenol ADHD lawsuits cannot go forward, judge rules
J&J to buy medical device maker V-Wave for up to $1.7 bln
J&J's chemotherapy-free treatment for lung cancer gets US approval
A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. But the real battle against the EGFR king has yet to start.
The National Advertising Division (NAD) has sided with Johnson & Johnson Consumer Inc (JJCI) in a row over ads for wound dressings, recommending ASO drop its “2x faster healing” claims for its hydrocolloid bandages.
J&J has enough support from claimants for $6.5-billion talc settlement, Bloomberg reports
Merck & Co. is paying $700 million upfront to challenge Amgen in a blood cancer market. The deal will give Merck global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific, positioning the Big Pharma as a rival to Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune disease.
Gilead is spending $320 million to buy out Johnson & Johnson’s global royalties for primary biliary cholangitis drug seladelpar a week before the FDA is
Johnson & Johnson MedTech has secured an FDA 510(k) clearance for its first robotically guided platform for spine surgery and has slated its commercial launch for the first half of next year.